Status:
COMPLETED
A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib modified release tablet taken once a day in patients with rheumatoid arthritis who continue taking methotrex...
Eligibility Criteria
Inclusion
- diagnosis of rheumatoid arthritis
- currently taking a stable dose of methotrexate
- no evidence of active or latent or inadequately treated tuberculosis
Exclusion
- evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or allergic disease
- clinically significant infections within the past 6 months
Key Trial Info
Start Date :
November 18 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2017
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT02281552
Start Date
November 18 2014
End Date
March 15 2017
Last Update
October 12 2018
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Japanese Red Cross Nagoya Daiichi Hospital
Nagoya, Aichi-ken, Japan, 453-8511
2
National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan, 460-0001
3
National Hospital Organization Toyohashi Medical Center
Toyohashi, Aichi-ken, Japan, 440-8510
4
Yamada Rheumatology Clinic
Matsuyama, Ehime, Japan, 790-0905